At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
350 mg Donepezil Transdermal Patch +1 moredrug
Likely dose
350 mg Donepezil Transdermal Patchfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Placebo-Controlled Study in Elderly Alzheimer's Patients on Established/Well Tolerated Dose of Aricept to Assess Skin Tolerability, Irritation, Adhesion With 3 Consecutive 7-Day Applications of 350 mg Donepezil Transdermal Patch
In Brief
A Phase 2 clinical trial evaluating 350 mg Donepezil Transdermal Patch and Placebo Patch for Irritation/Irritant. Completed, enrolled 49 participants across 7 sites.
Detailed Summary
This study is designed to assess skin tolerability, skin irritation, and adhesion of the 350 mg Donepezil Transdermal Patch (DTP-system), following 3, 7-day applications to 3 specific areas of the body (upper back, upper middle arm, side of torso) of elderly Alzheimer's patients. The total application time for the DTP-system is 21 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIrritation/Irritant
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2009
Primary CompletionJun 2009
First PostedJun 2009
TodayJul 2026
First PostedJun 9, 2009
Enrollment StartMay 1, 2009
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 17.1 years ago
Interventions
350 mg Donepezil Transdermal Patchdrug
Active and placebo patches will be applied to opposite sides for 7 days.
Placebo Patchdrug
Active and placebo patches will be applied to opposite sides for 7 days.